文献速递血管炎

巨细胞动脉炎复发的管理

Management of Relapses in Giant Cell Arteritis.
PubMed 文献 · Arthritis Rheumatol · 2025-01-20

约50%接受糖皮质激素单药治疗和30%接受托珠单抗辅助治疗的患者出现疾病复发,常发生在诊断后2年内;多数复发不危及生命或器官,但频繁复发增加糖皮质激素处方及治疗相关疾病负担,且托珠单抗停药后超过50%患者复发。本文从专家视角讨论巨细胞动脉炎复发的诊断与管理,综述国际指南推荐的治疗选择及新型潜在疗法。

要点

  • 约50%糖皮质激素单药治疗和30%托珠单抗辅助治疗患者出现复发,常发生在诊断后2年内。
  • 多数复发不危及生命或器官且可控制,但频繁复发增加糖皮质激素处方和治疗相关疾病负担。
  • 托珠单抗降低复发频率,但停药后超过50%患者复发;白细胞介素-6阻断抑制疾病活动但不恢复免疫耐受。

核心结论

  • 巨细胞动脉炎为复发性大血管炎,可致视力丧失及大动脉狭窄、动脉瘤和夹层等严重缺血表现。

研究设计与样本

  • 本文为专家视角综述,讨论巨细胞动脉炎复发的实际诊断与管理,并综述当前治疗选择及新型潜在疗法。

主要发现

  • 接受糖皮质激素单药治疗的患者中约50%出现疾病复发,接受托珠单抗辅助治疗的患者中约30%出现复发。
  • 复发常发生在诊断后2年内。
  • 多数复发不涉及危及生命或器官的表现且可成功控制。
  • 频繁复发可能导致糖皮质激素处方增加及相应治疗相关疾病负担,并增加进一步血管损伤风险。
  • 新出现的数据提示持续疾病活动可能导致血管疾病负担增加。

关键数值与推荐

  • 托珠单抗降低复发频率,但停药后超过50%患者复发。
  • 国际指南推荐的复发性巨细胞动脉炎治疗选择及新型潜在疗法在文中综述。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Giant cell arteritis (GCA) is a relapsing large vessel vasculitis with risk of serious ischemic manifestations, including vision loss and vascular damage in the form of large artery stenosis, aneurysms, and dissections. Approximately 50% of patients treated with glucocorticoid (GC) monotherapy and 30% of patients receiving adjunctive therapy with tocilizumab experience disease relapses, often during the first 2 years after diagnosis. Although most relapses in GCA do not involve life- or organ-threatening presentations and can be controlled successfully, frequent relapses may lead to increased prescription of GC and consequent treatment-related morbidity, in addition to risk of further vascular damage. Emerging data suggest that persistent disease activity may lead to increased vascular morbidity. Additionally, although tocilizumab decreases the frequency of relapses, more than 50% of patients relapse after discontinuation of therapy. Therefore, although interleukin-6 blockade suppresses disease activity, it does not restore tolerance. In this article, we discuss the practical diagnosis and management of GCA relapses from an expert perspective. Current treatment options for GCA relapses, including those recommended by international guidelines, and novel potential therapies are reviewed.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Alba MA, Unizony S, Warrington KJ, et al. Management of Relapses in Giant Cell Arteritis. Arthritis Rheumatol. 2025. PMID: 39711085. doi:10.1002/art.43098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。